These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16529141)

  • 21. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.
    Liossis SN; Sfikakis PP
    Clin Immunol; 2008 Jun; 127(3):280-5. PubMed ID: 18337174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immunological basis of B-cell therapy in systemic lupus erythematosus.
    Mok MY
    Int J Rheum Dis; 2010 Feb; 13(1):3-11. PubMed ID: 20374380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R; Albert D
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target.
    Dalakas MC
    Pharmacol Ther; 2006 Oct; 112(1):57-70. PubMed ID: 16644016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysfunctional B cells in systemic lupus erythematosus.
    Renaudineau Y; Pers JO; Bendaoud B; Jamin C; Youinou P
    Autoimmun Rev; 2004 Nov; 3(7-8):516-23. PubMed ID: 15546800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of nuclear factor-kappaB in the development of autoimmune diseases: a link between genes and environment.
    Kuryłowicz A; Nauman J
    Acta Biochim Pol; 2008; 55(4):629-47. PubMed ID: 19081854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.
    Taylor RP; Lindorfer MA
    Nat Clin Pract Rheumatol; 2007 Feb; 3(2):86-95. PubMed ID: 17299446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B cell targeted therapies in autoimmune diseases.
    Isenberg DA
    J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
    Kazkaz H; Isenberg D
    Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [B lymphocyte].
    Hasegawa M
    Nihon Rinsho Meneki Gakkai Kaishi; 2005 Oct; 28(5):300-8. PubMed ID: 16276043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Interleukin 10 in disseminated lupus erythematosus].
    Emilie D
    J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.
    Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2007 May; 66(5):700-3. PubMed ID: 17040963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of rituximab in patients with systemic lupus erythematosus: an update.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Galarza-Maldonado C; Sandoval-Cruz M; Zamudio-Huerta L; López-Colombo A; Cervera R
    Autoimmun Rev; 2009 Feb; 8(4):343-8. PubMed ID: 19036350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.
    Ahmed AR; Kaveri S
    Front Immunol; 2018; 9():1189. PubMed ID: 30072982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rituximab in systemic lupus erythematosus. Part I. Theoretical basis].
    Kardynał A; Rudnicka L
    Pol Merkur Lekarski; 2010 Aug; 29(170):131-4. PubMed ID: 20842829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B cell-targeted therapy in diseases other than rheumatoid arthritis.
    Looney RJ
    J Rheumatol Suppl; 2005 Feb; 73():25-8; discussion 29-30. PubMed ID: 15693113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data.
    Hawker K
    Curr Opin Neurol; 2008 Apr; 21 Suppl 1():S19-25. PubMed ID: 18388796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases.
    Lino AC; Dörner T; Bar-Or A; Fillatreau S
    Immunol Rev; 2016 Jan; 269(1):130-44. PubMed ID: 26683150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting of B cells in SLE: rationale and therapeutic opportunities.
    Silverman GJ
    Bull NYU Hosp Jt Dis; 2006; 64(1-2):51-6. PubMed ID: 17121490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.